Vidprevtyn is a protein-based vaccine designed to enable the body to produce antibodies to the virus. The vaccine uses the same technology as one of Sanofi’s seasonal flu vaccines. GSK provides an adjuvant.
According to available data from laboratory tests and the first clinical studies in adults, the product could protect against covid-19, the EMA said.
The ongoing process will continue until the Agency has sufficient evidence to accept the application for registration of the vaccine on the European Union market.
It is not yet clear when the evaluation process will be completed. Sanofi Pasteur and GSK believe in approval by the end of the year, Reuters said. The EMA only recommends the approval of the vaccine, the final decision on registration on the EU market is up to the European Commission.
To date, four covid-19 vaccines from Pfizer / BioNTech, Moderna, AstraZeneca and Johnson & Johnson have been approved in the EU. The EMA is currently assessing four other vaccines – CureVac, Novavax, Sinovac and Sputnik V.